Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
24 studies found for:    "Richter syndrome"
Show Display Options
Rank Status Study
1 Recruiting A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome
Condition: Richter Syndrome
Interventions: Drug: Venetoclax;   Other: DA-EPOCH-R
2 Active, not recruiting Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Condition: Richter's Syndrome
Intervention: Drug: Ofatumumab
3 Not yet recruiting Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
Conditions: Richter's Syndrome;   CLL
Intervention: Drug: Obinutuzumab, lenalidomide, HDMP
4 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Conditions: Mediastinal Large B-cell Lymphoma;   Richter Syndrome
Intervention: Biological: Pembrolizumab
5 Terminated Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Condition: Richter's Transformation
Intervention: Drug: selinexor
6 Terminated PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Condition: Richter's Transformation
Intervention: Drug: PNT2258
7 Not yet recruiting Study of Blinatumomab in Richter Transformation
Conditions: Hematopoietic/Lymphoid Cancer;   Richter's Transformation
Interventions: Drug: Blinatumomab;   Drug: Dexamethasone
8 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Conditions: Richter's Transformation;   Leukemia
Interventions: Drug: Oxaliplatin;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Pegfilgrastim
9 Completed VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Conditions: Leukemia;   Lymphoma
Intervention: Drug: laromustine
10 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Condition: Leukemia
Interventions: Drug: Cytarabine;   Drug: Fludarabine;   Drug: Oxaliplatin;   Drug: Rituximab
11 Active, not recruiting ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Richter's Syndrome;   Prolymphocytic Leukemia
Intervention: Drug: acalabrutinib
12 Recruiting Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Pembrolizumab;   Drug: TGR-1202;   Biological: ublituximab
13 Completed Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
14 Withdrawn Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
Conditions: Prolymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome
Interventions: Drug: sotrastaurin acetate;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Recruiting Registry of the German CLL Study Group
Conditions: CLL;   SLL;   HCL;   Richter´s Transformation;   Leukemia, Prolymphocytic, B-Cell;   Leukemia, Prolymphocytic, T-Cell;   T-LGL Leukemia;   NK-LGL Leukemia
Intervention:
16 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
17 Completed
Has Results
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Prolymphocyctic Leukemia;   Richter's Transformation
Interventions: Drug: PCI-32765;   Drug: ofatumumab
18 Recruiting ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Conditions: Non-hodgkin Lymphoma;   Multiple Myeloma;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Richter's Syndrome;   Waldenstrom Macroglobulinemia
Interventions: Drug: Acalabrutinib;   Drug: Pembrolizumab
19 Not yet recruiting Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Conditions: Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
20 Recruiting Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.